Apoptosis oxidative damage‐mediated and antiproliferative effect of selenylated imidazo[1,2‐a]pyridines on hepatocellular carcinoma HepG2 cells and in vivo
Authors:
- Daniela Coelho dos SantosDSDaniela Coelho dos Santos
- Jamal RafiqueJamal Rafique
- Sumbal SabaSumbal Saba
- Gabriela M. AlmeidaGAGabriela M. Almeida
- Tâmila SiminskiTSTâmila Siminski
- Cynthia PáduaCPCynthia Pádua
- Danilo W. FilhoDFDanilo W. Filho
- Ariane ZamonerAriane Zamoner
- Antonio L. BragaABAntonio L. Braga
- Rozangela C. PedrosaRPRozangela C. Pedrosa
- Fabiana OuriqueFOFabiana Ourique
- 30 October 2020
- journal article
- research article
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 35 (3) , e22663
Abstract
Imidazo[1,2‐a]pyridines (IP) and organoselenium compounds have been widely exploited in medicinal chemistry due to their pharmacological activities. Hepatocellular carcinoma (HCC) has few treatment options, and unfortunately, the prognosis is poor. Thus, the development of novel therapeutic drugs is urgent. The present study aimed at evaluating the antitumor mechanism of selenylated IP against HepG2 cells and in vivo. The selenylated IP named IP‐Se‐06 (3‐((2‐methoxyphenyl)selanyl)‐7‐methyl‐2‐phenylimidazol[1,2‐a]pyridine) showed high cytotoxicity against HepG2 cells (half‐maximal inhibitory concentration [IC50] = 0.03 µM) and selectivity for this tumor cell line. At nontoxic concentration, IP‐Se‐06 decreased the protein levels of Bcl‐xL and increased the levels of p53, leading to inhibition of cell proliferation and apoptosis. This compound decreased the level of extracellular signal‐regulated kinase 1/2 protein and changed the levels of proteins involved in the drive of the cell cycle, tumor growth, and survival (cyclin B1, cyclin‐dependent kinase 2). In addition, IP‐Se‐06 decreased the number of cells in the S phase. In addition, IP‐Se‐06 led to increased generation of reactive oxygen species, changed antioxidant defenses, and caused DNA fragmentation. Finally, IP‐Se‐06 significantly inhibited the growth of Ehrlich ascites tumors in mice, increased survival time, and inhibited angiogenesis. Therefore, IP‐Se‐06 may be an important compound regarding the development of a therapeutic drug for HCC treatment.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (303234/2015‐6, 305297/2016‐3, 433896/2018‐3)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (001)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
This publication has 62 references indexed in Scilit:
- Design and Synthesis of Imidazopyridine Analogues as Inhibitors of Phosphoinositide 3-Kinase Signaling and AngiogenesisJournal of Medicinal Chemistry, 2011
- Selenium activates p53 and p38 pathways and induces caspase-independent cell death in cervical cancer cellsCell Biology and Toxicology, 2007
- Clonogenic assay of cells in vitroNature Protocols, 2006
- Discovery and development of sorafenib: a multikinase inhibitor for treating cancerNature Reviews Drug Discovery, 2006
- Updated treatment approach to hepatocellular carcinomaJournal of Gastroenterology, 2005
- A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicinBiochemical Pharmacology, 1999
- The single cell microgel electrophoresis assay (comet assay): technical aspects and applicationsMutation Research/DNA Repair, 1995
- A simple technique for quantitation of low levels of DNA damage in individual cellsExperimental Cell Research, 1988
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958